idelalisib + BI 836826

Idelalisib + BI 836826 is a **combination therapy** consisting of idelalisib, an oral small molecule inhibitor of the phosphoinositide 3-kinase delta (PI3Kδ), and BI 836826, a chimeric mouse–human monoclonal antibody directed against CD37, a tetraspanin transmembrane protein expressed on mature B lymphocytes. Idelalisib disrupts leukemic B-cell survival networks in the microenvironment, facilitating the egress of chemoresistant, relapse-initiating B-cell subpopulations from lymph nodes into the blood. BI 836826 targets CD37 and triggers antibody-dependent cell-mediated cytotoxicity and direct proapoptotic effects in B-cell malignancies. The combination enhances cytotoxicity against chronic lymphocytic leukemia (CLL) cells, particularly in relapsed or refractory settings, representing a rational therapeutic approach for CLL by targeting distinct survival pathways[1][3][5].

Other names

idelalisib + BI 836826